Translational approaches to functional platelet production ex vivo

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 250-256

  Balduini, Alessandra ^a,b,c   Di Buduo, Christian A ^a,b   Kaplan, David L ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Tufts University   (United States)

Author keywords

Bioreactor; Bone marrow; Ex vivo platelet production; Megakaryocytes

Indexed keywords

CD63 ANTIGEN; COLLAGEN; DIMETICONE; ERYTHROPOIETIN; FIBRONECTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 6; LAMININ; LEUKEMIA INHIBITORY FACTOR; PADGEM PROTEIN; POLYCARBONATE; RISTOCETIN; STROMAL CELL DERIVED FACTOR 1ALPHA; BIOMATERIAL;

BIOCOMPATIBILITY; BIOREACTOR; BLOOD CLOTTING; BONE MARROW; CELL MATURATION; CELL PROLIFERATION; CELL VIABILITY; EMBRYONIC STEM CELL; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; HYDRODYNAMICS; IMMUNOFLUORESCENCE MICROSCOPY; MEGAKARYOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPOIESIS; TISSUE ENGINEERING; ANIMAL; BIOENGINEERING; BONE MARROW CELL; CHEMISTRY; CYTOLOGY; INFLAMMATION; METABOLISM; PHENOTYPE; PHYSIOLOGY; PROCEDURES; STEM CELL; THROMBOCYTE; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOENGINEERING; BIOREACTORS; BLOOD PLATELETS; BONE MARROW; BONE MARROW CELLS; HUMANS; INFLAMMATION; MEGAKARYOCYTES; PHENOTYPE; STEM CELLS; THROMBOPOIESIS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84957109136     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-07-0570     Document Type: Review

References (73)

1. Michel SG, Madariaga ML, Villani V, et al. Current progress in xenotransplantation and organ bioengineering. Int J Surg 2015; 13: 239-244.
2. Benam KH, Dauth S, Hassell B, et al. Engineered in vitro disease models. Annu Rev Pathol 2015; 10: 195-262.
3. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 2015; 14: 248-260.
4. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature 2014; 505: 327-334.
5. Geddis AE, Kaushansky K. Immunology. The root of platelet production. Science 2007; 317: 1689-1691.
6. Owens M, Holme S, Heaton A, et al. Post-transfusion recovery of function of 5-day stored platelet concentrates. Br J Haematol 1992; 80: 539-544.
7. Cardigan R, Williamson LM. The quality of platelets after storage for 7 days. Transfus Med 2003; 13: 173-187.
8. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4-15.
9. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-1508.
10. Anitua E, Sánchez M, Nurden AT, et al. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006; 24: 227-234.
11. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 2013; 9: 721-730.
12. Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet 2013; 381: 1866-1875.
13. Estcourt LJ. Why has demand for platelet components increased? A review. Transfus Med 2014; 24: 260-268.
14. Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol 2013; 161: 778-793.
15. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Haematol 2012; 19: 392-398.
16. Oshima Y, Yuji K, Tanimoto T, et al. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Intern Med 2013; 52: 2193-2201.
17. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424-430.
18. Ellis SL, Grassinger J, Jones A, et al. The relationship between bone, haemopoietic stem cells, and vasculature. Blood 2011; 118: 1516-1524.
19. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339-3347.
20. Pang L, Weiss MJ, Poncz M. Megakaryocyte biology and related disorders. J Clin Invest 2005; 115: 3332-3338.
21. Hamada T, Möhle R, Hesselgesser J, et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 1998; 188: 539-548.
22. Italiano JE, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost 2003; 1: 1174-1182.
23. Avecilla ST, Hattori K, Heissig B, et al. Chaemokine-mediated interaction of haematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71.
24. Junt T, Schulze H, Chen Z, et al. Dynamic visualisation of thrombopoiesis within bone marrow. Science 2007; 317: 1767-1770.
25. Nishimura S, Nagasaki M, Kunishima S, et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol 2015; 209: 453-466.
26. Charras G, Sahai E. Physical influences of the extracellular environment on cell migration. Nat Rev Mol Cell Biol 2014; 15: 813-824.
27. Malara A, Gruppi C, Pallotta I, et al. Extracellular matrix structure and nanomechanics determine megakaryocyte function. Blood 2011; 118: 4449-4453.
28. Di Buduo CA, Wray LS, Tozzi L, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. Blood 2015; 125: 2254-2264.
29. Kim DH, Provenzano PP, Smith CL, et al. Matrix nanotopography as a regulator of cell function. J Cell Biol 2012; 197: 351-360.
30. Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. Science 2005; 310: 1139-1143.
31. Shin JW, Swift J, Spinler KR, et al. Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular projections typical of platelet-producing megakaryocytes. Proc Natl Acad Sci USA 2011; 108: 11458-11463.
32. Tangelder GJ, Slaaf DW, Arts T, et al. Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. Am J Physiol 1988; 254: H1059-1064.
33. Mazo IB, von Andrian UH. Adhesion and homing of blood-borne cells in bone marrow microvessels. J Leukoc Biol 1999; 66: 25-32.
34. Zhang L, Orban M, Lorenz M, et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med 2012; 209: 2165-2181.
35. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009; 16: 58-83.
36. Neeves KB, Onasoga AA, Wufsus AR. The use of microfluidics in haemostasis: clinical diagnostics and biomimetic models of vascular injury. Curr Opin Haematol 2013; 20: 417-423.
37. Dunois-Lardé C, Capron C, Fichelson S, et al. Exposure of human megakaryocytes to high shear rates accelerates platelet production. Blood 2009; 114: 1875-1883.
38. Jiang J, Woulfe DS, Papoutsakis ET. Shear enhances thrombopoiesis and formation of microparticles that induce megakaryocytic differentiation of stem cells. Blood 2014; 124: 2094-2103.
39. Torisawa YS, Spina CS, Mammoto T, et al. Bone marrow-on-a-chip replicates haematopoietic niche physiology in vitro. Nat Methods 2014; 11: 663-669.
40. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol 2014; 32: 760-772.
41. Sullenbarger B, Bahng JH, Gruner R, et al. Prolonged continuous in vitro human platelet production using three-dimensional scaffolds. Exp Haematol 2009; 37: 101-110.
42. Lasky LC, Sullenbarger B. Manipulation of oxygenation and flow-induced shear stress can increase the in vitro yield of platelets from cord blood. Tissue Eng Part C Methods 2011; 17: 1081-1088.
43. Nakagawa Y, Nakamura S, Nakajima M, et al. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. Exp Haematol 2013; 41: 742-748.
44. Schlinker AC, Radwanski K, Wegener C, et al. Separation of in-vitro-derived megakaryocytes and platelets using spinning-membrane filtration. Biotechnol Bioeng 2015; 112: 788-800.
45. Thon JN, Mazutis L, Wu S, et al. Platelet bioreactor-on-a-chip. Blood 2014; 124: 1857-1867.
46. Feng Q, Shabrani N, Thon JN, et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports 2014; 3: 817-831.
47. Omenetto FG, Kaplan DL. New opportunities for an ancient material. Science 2010; 329: 528-531.
48. Pallotta I, Lovett M, Kaplan DL, et al. Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes. Tissue Eng Part C Methods 2011; 17: 1223-1232.
49. Malara A, Currao M, Gruppi C, et al. Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin. Stem Cells 2014; 32: 926-937.
50. Avraham H, Cowley S, Chi SY, et al. Characterisation of adhesive interactions between human endothelial cells and megakaryocytes. J Clin Invest 1993; 91: 2378-2384.
51. Thiele W, Krishnan J, Rothley M, et al. VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis. Blood 2012; 120: 1899-1907.
52. Pitchford SC, Lodie T, Rankin SM. VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. Blood 2012; 120: 2787-2795.
53. Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85: 402-413.
54. Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol 2014; 165: 259-268.
55. Balduini A, Pallotta I, Malara A, et al. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost 2008; 6: 1900-1907.
56. Balduini A, Malara A, Balduini CL, et al. Megakaryocytes derived from patients with the classical form of Bernard-Soulier syndrome show no ability to extend proplatelets in vitro. Platelets 2011; 22: 308-311.
57. Lambert MP, Sullivan SK, Fuentes R, et al. Challenges and promises for the development of donor-independent platelet transfusions. Blood 2013; 121: 3319-3324.
58. Avanzi MP, Mitchell WB. Ex vivo production of platelets from stem cells. Br J Haematol 2014; 165: 237-247.
59. Balduini A, Badalucco S, Pugliano MT, et al. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS One 2011; 6: e21015.
60. Currao M, Balduini CL, Balduini A. High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes. PLoS One 2013; 8: e54723.
61. Di Buduo CA, Moccia F, Battiston M, et al. The importance of calcium in the regulation of megakaryocyte function. Haematologica 2014; 99: 769-778.
62. Bluteau D, Balduini A, Balayn N, et al. Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest 2014; 124: 580-591.
63. Espasandin YR, Glembotsky AC, Grodzielski M, et al. Anagrelide plateletlowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. J Thromb Haemost 2015; 13: 631-642.
64. Shao Y, Sang J, Fu J. On human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology. Biomaterials 2015; 52: 26-43.
65. Gaur M, Kamata T, Wang S, et al. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost 2006; 4: 436-442.
66. Takayama N, Nishikii H, Usui J, et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate haematopoietic progenitors. Blood 2008; 111: 5298-5306.
67. Lu SJ, Li F, Yin H, et al. Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res 2011; 21: 530-545.
68. Pick M, Azzola L, Osborne E, et al. Generation of megakaryocytic progenitors from human embryonic stem cells in a feeder-and serum-free medium. PLoS One 2013; 8: e55530.
69. Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010; 207: 2817-2830.
70. Nakamura S, Takayama N, Hirata S, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell 2014; 14: 535-548.
71. Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev 2001; 15: 175-180.
72. Riolobos L, Hirata RK, Turtle CJ, et al. HLA engineering of human pluripotent stem cells. Mol Ther 2013; 21: 1232-1241.
73. Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale. Blood 2015; 125: 3627-3636.